Article thumbnail

Peripheral Vascular Dysfunction in Chronic Kidney Disease

By Christopher R. Martens and David G. Edwards


There is an increased prevalence of cardiovascular disease- (CVD-) related mortality in patients with chronic kidney disease (CKD). Endothelial dysfunction is a primary event in the development of atherosclerosis and hypertension and likely contributes to the elevated cardiovascular risk in CKD. Endothelial dysfunction has been shown to occur in the peripheral vasculature of patients with both severe and moderate CKD. Mechanisms include oxidative stress, L-arginine deficiency, and elevated plasma levels of ADMA. Interventions designed to restore vascular function in patients with CKD have shown mixed results. Evidence from cell culture studies suggest that the accumulation of uremic toxins inhibits L-arginine transport and reduces nitric oxide production. The results of these studies suggest that endothelial dysfunction may become less reversible with advancing kidney disease. The purpose of this paper is to present the current literature pertaining to potential mechanisms of peripheral vascular dysfunction in chronic kidney disease and to identify possible targets for treatment

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2002). A .S .L e v e y ,J .C o r e s h ,K .B o l t o ne ta l .
  2. (2002). a g n e r ,J .D .K l e i n ,J .M .S a n d s ,a n dC .B a y l i s ,“ U r e a transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport,”
  3. (1988). a l m e r ,D .S .A s h t o n ,a n dS .M o n c a d a ,“ V a s c u l a r endothelial cells synthesize nitric oxide from
  4. (2010). a n dY . Xiong, “Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells,” Atherosclerosis,
  5. (2003). a y o u b ,V .A c h a n ,S .A d i m o o l a me ta l . ,“ D i m e t h y l a r g i -nine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence,”
  6. (1992). Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,”
  7. (2001). Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure,” Kidney International,v o l .6 0 ,n o .6 ,p p .
  8. (2007). Alfthan et al., “Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study,” Circulation,v o l .
  9. (1999). andB.Mayer, “Enzymatic function ofnitric oxide synthases,”
  10. (1991). Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta,” Circulation,v o l .
  11. (2006). Arginine, arginine analogs and nitric oxide production in chronic kidney disease,”
  12. (2005). Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study,”
  13. (2003). Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase,”
  14. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor,”
  15. (2009). Asymmetric dimethylarginineandmortalityinstages3to4chronickidneydisease,”
  16. (1999). B¨ og e r ,S.M.Bod e - B¨ ogeret al.,“Asymmetric dimethylarginine plasma concentrations differ in patients withend-stagerenaldisease:relationshiptotreatment method and atherosclerotic disease,”
  17. (2003). Bode-B¨ o g e r ,J .M u k e ,A .S u r d a c k i ,G .B r a b a n t ,R .H . B¨ oger,andJ.C.Fr¨ olich,“OralL-arginineimprovesendothelial function in healthy individuals older than 70 years,”
  18. (1997). C h e n ,J .M .L i a w ,J .G .J u a n g ,a n dT .E .H .L i n , “Antioxidant enzymes and trace elements in hemodialyzed patients,”
  19. (2006). Caglar et al., “The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine,”
  20. (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England
  21. (2002). Coordinate regulation of Larginine uptake and nitric oxide synthase activity
  22. (2002). Cyclooxygenase inhibition improves endothelium-dependent vasodilation in patients with chronic renal failure,”
  23. (2011). Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients,”
  24. (2008). Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure,” Pediatric Nephrology,
  25. (2005). e i t z e r ,S .B a l d u s ,Y .v o nK o d o l i t s c h ,V .R u d o l p h ,a n d T. Meinertz, “Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure,” Arteriosclerosis, Thrombosis, and Vascular Biology,
  26. (2004). Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats,”
  27. (2004). Endothelial dysfunction and oxidative stress in chronic renal failure,”
  28. (2010). Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients,”
  29. (2005). Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death,”
  30. (2006). Endothelial dysfunction: am u l t i f a c e t e dd i s o r d e r ,
  31. Endothelial function and oxidative stress in cardiovascular diseases,”
  32. (2005). Fellstr¨ om, “Endothelial function, CRP and oxidative stress in chronic kidney disease,”
  33. (2008). Flow-mediated vasodilatation of the brachial artery in children with chronic kidney disease,”
  34. (2009). Galvao de Lima, “Oxidative stress and endothelial dysfunction in chronic kidney disease,”
  35. (2003). Glorieux et al., “Review on uremic toxins: classification, concentration, and interindividual variability,”Kidney
  36. (2008). Habitual exercise and arterial aging,”
  37. (2007). Homocysteineinduces endothelialdysfunction viainhibition ofargininetransport,”JournalofPhysiologyandPharmacology,
  38. (2005). Hriljac et al., “Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure,”
  39. (1987). I g n a r r o ,G .M .B u g a ,K .S .W o o d ,R .E .B y r n s ,a n dG . Chaudhuri, “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide,”
  40. (2008). i n d e n ,W .C a i ,J .C .H ee ta l . ,“ E n d o t h e l i a ld y s f u n c -tion in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition ofendothelialnitricoxidesynthasethroughRAGEactivation,”
  41. (2006). I s b e l ,B .H a l u s k a ,D .W .J o h n s o n ,E .B e l l e r ,C .H a w l e y
  42. (2010). i t i a ,L .T o m a s o n i ,F .A t z e n ie ta l . ,“ F r o me n d o t h e l i a l dysfunction to atherosclerosis,”Autoimmunity Reviews,v o l .9
  43. (2003). Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study,”
  44. (2001). Impaired endothelial function in isolated human uremic resistance arteries,”
  45. (2001). Impaired endothelium-dependent vasodilatation in renal failure in humans,”
  46. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: Ramipril versus valsartan,”BloodPurification,
  47. (2004). Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease,”
  48. (2002). J.Bernheim,and M.Rathaus,“Endothelialdysfunctionandhypertensionin5/6 nephrectomized rats are mediated by vascular superoxide,”
  49. (2005). Kielstein andC.Zoccali,“Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?”
  50. (1996). l a r k s o n ,M .R .A d a m s ,A .J .P o w ee ta l . ,“ O r a lL - a r g i n i n e improves endothelium-dependent dilation in hypercholesterolemic young adults,”
  51. (2004). L o n d o n ,B .P a n n i e r ,M .A g h a r a z i i
  52. (2010). M.Goicoechea,S.GarciadeV inuesa,U .V erdallesetal.,“Effect of allopurinol in chronic kidney disease progression and cardiovascular risk,”
  53. (2003). Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies,”
  54. (2006). Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease,”
  55. (2008). Nitric oxide deficiency in chronic kidney disease,”
  56. (1999). Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis,”
  57. (1992). Noninvasive detection of endothelial dysfunction
  58. (2006). o r a d i ,V .K w o k ,a n dN .D .V a z i r i ,“ E ffect of chronic renal failure on arginase and argininosuccinate synthetase expression,” American Journal of Nephrology,v ol.26,no .3,p p .
  59. (2010). o r o n d e l ,M .N a n d i ,P .K e l l y ,B .W o j c i a k - S t o t h a r d ,I .F l e m
  60. (2001). Oxidative stress and endothelial function in chronic renal failure,” J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y ,v o l
  61. (2003). Oxidative stress as a therapeutic target in diabetes: revisiting the controversy,”
  62. (1997). Physiology and biochemistry of endothelial function in children with chronic renal failure,”
  63. (2003). Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey,”
  64. (2008). R .E .P u r d y ,a n dN .D .V a z i r i ,“ E ffect of exercise training on aortic tone in chronic renal insufficiency,”
  65. (2009). Review article: getting the balance right: assessingcauses and extent ofvascular calcification in chronic kidney disease,”
  66. (2007). Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications,”
  67. (1994). Role of arginine in health and in renal disease,”
  68. (2004). Role of endothelial dysfunction in atherosclerosis,”
  69. (2001). S.Xiao,L.Wagner,J.Mahaney,andC.Baylis,“Uremiclevelsof urea inhibitL-argininetransportincultured endothelialcells,”
  70. (2000). Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial,”
  71. (2009). Sonmez et al., “Effect of renin angiotensin system blockade on pentraxin 3 levels in type2 diabetic patients with proteinuria,”
  72. (2000). Sydow,J.Borlak et al.,“LDL cholesterolupregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethioninedependent methyltransferases,”
  73. (2002). Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines,”
  74. (2003). The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial,”
  75. (1993). The endothelium as a regulator of vascular smooth muscle proliferation,”
  76. (1993). The L-arginine-nitric oxide pathway,” The New England
  77. (2004). The role of oxidative stressaltered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction,” J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y ,
  78. (2003). The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications,”
  79. (1991). u b e s ,M .S u z u k i ,a n dD .N .G r a n g e r ,“ N i t r i co x i d e :a n endogenous modulator of leukocyte adhesion,”
  80. (2002). u n t n e r ,J .H e ,L .H a m m ,C .L o r i a ,a n dP .K .W h e l t o n , “Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States,”
  81. (2002). V a z i r i ,Z .N i ,F .O v e i s i ,K .L i a n g ,a n dR .P a n d i a n , “Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency,”
  82. (2006). Vascular NADPH oxidases as drug targets for novel antioxidant strategies,”
  83. (2003). Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure,” Kidney International,v o l .
  84. (2005). Zoccali,“Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach,”